Australia markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.9229-0.0477 (-4.91%)
At close: 04:00PM EDT
0.9200 -0.00 (-0.31%)
Pre-market: 09:14AM EDT

bluebird bio, Inc.

455 Grand Union Boulevard
Somerville, MA 02145
United States
339 499 9300
https://www.bluebirdbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees323

Key executives

NameTitlePayExercisedYear born
Mr. Andrew ObenshainPresident, CEO & Director1.04MN/A1974
Mr. Thomas J. KlimaChief Commercial Officer & COO654.97kN/A1972
Mr. Richard A. Colvin M.D., Ph.D.Chief Medical Officer696.24kN/A1966
Mr. Christopher Krawtschuk CPACFO, Principal Accounting Officer & TreasurerN/AN/A1974
Mr. Joseph D. Vittiglio Esq., J.D.Chief Legal & Business Officer and SecretaryN/AN/A1972
Jess RowlandsHead of Corporate CommunicationsN/AN/AN/A
Ms. Andrea WaltonChief People OfficerN/AN/AN/A
Mr. Kasra KasraianSenior Vice President of Technical Development & OperationsN/AN/AN/A
Mr. Scott ShoemakerSenior Vice President of QualityN/AN/AN/A
Ms. Sarah AlspachSenior Vice President of External AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Corporate governance

bluebird bio, Inc.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.